KFDA announces voluntary withdrawal of Zelmac

The Korea Food and Drug Administration (KFDA) announced on April 2 that Novartis Korea has halted sales of Zelmac (tegaserod), its agent for irritable bowel syndrome and constipation, following suggestions of a small increase in ischemic events, including angina and stroke, in those taking the drug.

The company will voluntarily remove Zelmac from the market.

The ischemic events came to li...